Price:
Rs. 60,000.00
Sample Type: EDTA Whole Blood , Tissue
Fasting Not Required
Notes:N8293
Frequently Asked Questions (FAQ's):
What does the NextGen Targeted & Immunotherapy Advanced Panel include?
It assesses a wide range of oncology genes, actionable mutations, tumor biomarkers, and pathways linked to targeted drugs and immunotherapy response.
Why is this test important?
It helps identify genetic alterations that determine treatment sensitivity, resistance, and eligibility for precision therapies, including immunotherapy.
Who should take this test?
Patients with newly diagnosed, advanced, or treatment-resistant solid tumors may benefit from this comprehensive genomic analysis.
How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-depth Next Generation Sequencing combined with advanced bioinformatics to deliver accurate and actionable molecular findings.
What type of sample is required?
Tumor tissue (FFPE block or slides) or, in some cases, peripheral blood, depending on clinical suitability.
Is any special preparation required?
No special preparation is needed, though adequate tumor content in the sample is essential for optimal analysis.
How soon are the results available?
Metropolis Healthcare provides detailed molecular reports within a clinically appropriate timeframe to support timely treatment decisions.
Can this test guide treatment choices?
Yes, it helps clinicians select targeted therapies, immunotherapy options, clinical trial eligibility, and personalized treatment strategies based on genomic findings